Table 3.
Normal cluster |
Abnormal cluster |
p value |
|
---|---|---|---|
Number of patients | 39 | 11 | |
IPSS score | |||
Low / Intermediate-1 | 21 (55%) | 2 (18%) | |
Intermediate-2 / High / MDS-AML | 17 (45%) | 9 (82%) | 0.031 |
NA | 1 | ||
WHO classification | |||
<5% bone marrow blasts | 18 (46%) | 1 (9%) | |
>5% bone marrow blasts | 16 (41%) | 8 (73%) | 0.027 |
Chronic myelomonocytic leukemia | 5 (13%) | 2 (18%) | |
Infection | 8 (21%) | 3 (27%) | 0.69 |
History of transfusion | |||
Yes | 24 (70%) | 7 (70%) | 0.67 |
No | 10 (30%) | 3 (30%) | |
NA | 5 | 1 | |
Peripheral blood lymphocyte count (median) | 1410 | 1310 | 0.37 |
WT1 expression (median) | 0.0062 | 0.034 | 0.047 |
Bone marrow blasts at sample (median) | 2 | 10 | 0.056 |
Peripheral blood lymphocyte count (median) | 1410 | 1310 | 0.37 |
Bone marrow cellularity | |||
Hypocellular | 6 (15%) | 3 (27%) | 0.4 |
Normocellular / Hypercellular | 28 (71%) | 7 (63%) | |
NA | 5 | 1 | |
Previous Treatment | |||
Growth Factor | 20 | 3 | 0.189 |
5’ Azacytidine | 4 | 6 | 0.004 |
Anthi-thymocyte globulin | 3 | 0 | 0.4 |
Thalidomide / lenalidomide | 7 | 1 | 0.66 |
Cytotoxic Chemotherapy | 4 | 2 | 0.6 |